[Skip to Navigation]
January 1964

Chemotherapy of Experimental Toxoplasmosis: Evaluation of Spiramycin Alone and in Combination

Author Affiliations

Detroit, Mich; Bethesda, Md
From the Ophthalmology Branch, National Institute of Neurological Diseases and Blindness, and the Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Public Health Service, United States Department of Health, Education and Welfare.

Arch Ophthalmol. 1964;71(1):119-127. doi:10.1001/archopht.1964.00970010135021

Introduction  A new antibiotic, spiramycin, isolated from Streptomyces ambofaciens found in soil from the north of France was shown by Garin and Eyles1 to be effective in the treatment of experimentally induced murine toxoplasmosis. This finding prompted Chodos and Habegger-Chodos to use the drug in a series of 67 patients in this country in 1961.2 They concluded that spiramycin was an effective agent for use in posterior uveitis presumably caused by Toxoplasma and suggested that it replace pyrimethamine and sulfadiazine as the treatment of choice in posterior uveitis. Fajardo, Furgiuele, and Leopold,3 however, reported a series of 87 patients who had received either spiramycin and steroids, sulfadiazine, pyrimethamine (Daraprim) and steroids, or steroid therapy alone, including in this report many of the cases treated by Chodos and Habegger-Chodos and found that, although spiramycin therapy resulted in quiescence of the posterior uveitis, sulfadiazine and pyrimethamine appeared much more

Add or change institution